Market capitalization | $2.21m |
Enterprise Value | $24.72m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.26 |
P/S ratio (TTM) P/S ratio | 0.11 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 24.72% |
Revenue (TTM) Revenue | $19.66m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
2 Analysts have issued a Acutus Medical Inc forecast:
2 Analysts have issued a Acutus Medical Inc forecast:
Sep '23 |
+/-
%
|
||
Revenue | 20 20 |
25%
25%
|
|
Gross Profit | -12 -12 |
32%
32%
|
|
EBITDA | -66 -66 |
31%
31%
|
EBIT (Operating Income) EBIT | -72 -72 |
30%
30%
|
Net Profit | -33 -33 |
62%
62%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Acutus Medical, Inc. engages in the development of medical devices and electrophy equipment. It creates electrophysiological mapping systems for the treatment of cardiac arrhythmias, such as atrial fibrillation, and ventricular tachycardia. The company was founded by Randell L. Werneth and Christoph Scharf in 2011 and is headquartered in Carlsbad, CA.
Head office | United States |
CEO | Takeo Mukai |
Employees | 233 |
Founded | 2011 |
Website | www.acutusmedical.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.